Khadija Panhwar

Khadija Panhwar

Auto-generated profile, based on publicly available information

Khadija Panhwar

Dow University of Health Sciences, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2026 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
NANouraiz Abbas
Nouraiz Abbas
AMAdil Ahmed Memon
Adil Ahmed Memon
RZRumaisa Zulfiqar
Rumaisa Zulfiqar
ANAqsa Zahoor Noon
Aqsa Zahoor Noon
SSSyed Mohamin Abbas Shah
Syed Mohamin Abbas Shah
IHIftikhar Hayat
Iftikhar Hayat
Background: Individuals with schizophrenia spectrum disorders experience a high burden of metabolic abnormalities, which are further exacerbated by antipsychotic treatment and contribute to increased cardiovascular morbidity and premature mortality. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated metabolic benefits in the general population; however, their effectiveness and safety in individuals with schizophrenia remain uncertain. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of semaglutide and other GLP-1 receptor agonists on metabolic outcomes in adults with schizophrenia spectrum disorders receiving antipsychotic treatment. The review was conducted in accordance with PRISMA 2020 guidelines, with the protocol prospectively registered in PROSPERO (CRD420251248437). Electronic databases were searched from inception to the final search date. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and certainty of evidence was evaluated using the GRADE approach. Random-effects meta-analyses were performed. Results: Seven randomized controlled trials involving 446 participants were included. GLP-1 receptor agonist therapy was associated with a statistically significant reduction in body weight compared with control (−6.10 [95% CI: −12.10 to −0.10], P =0.05) although heterogeneity was substantial (I²=99%). Significant reductions were also observed in body mass index, waist circumference, and fasting plasma glucose. Effects on lipid parameters, insulin-related outcomes, and blood pressure were inconsistent and generally not statistically significant. Serious adverse events were less frequent in the intervention group. The certainty of evidence ranged from low to moderate, primarily due to heterogeneity and imprecision. Conclusions: GLP-1 receptor agonists are associated with statistically significant improvements in body weight and selected glycemic parameters among adults with schizophrenia spectrum disorders treated with antipsychotics. However, substantial heterogeneity, shorter study population, and low certainty of evidence restrict the strength of these conclusions. Larger, well-designed randomized controlled trials with longer follow-up and standardized outcome reporting are needed to better define the efficacy and safety of GLP-1 receptor agonists in this population.

5 September 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
AAAbel Aizeque
Abel Aizeque
DLDiksha Ladhani
Diksha Ladhani
BTBibi Zarfeen Talpur
Bibi Zarfeen Talpur
KPKhadija Panhwar
Khadija Panhwar
AAArchita Archita
Archita Archita
TOToluwase Oluwajomiloju Ogundipe
Toluwase Oluwajomiloju Ogundipe
Endomyocardial fibrosis (EMF) is a neglected restrictive cardiomyopathy reported predominantly in tropical regions. In Mozambique, the published evidence i